CDTTW Stock Financials: Financial Performance and Reports

Period	FY-2023	FY-2022	FY-2021
Period Ended	12/31/2023	12/31/2022	12/31/2021
Operating Revenue	$0.00	$0.00	$0.00
Cost of Revenue	$0.00	$0.00	$0.00
Gross Profit	$0.00	$0.00	$0.00
Gross Profit Ratio	0	0	0
Research and Development Expenses	$90,000.00	$111,000.00	$283,000.00
General & Administrative Expenses	$0.00	$3.05 M	$2.89 M
Selling & Marketing Expenses	$0.00	$0.00	$0.00
Selling, General & Administrative Expenses	$5.47 M	$3.05 M	$2.89 M
Other Expenses	$0.00	$0.00	$0.00
Operating Expenses	$5.56 M	$3.16 M	$3.17 M
Cost And Expenses	$5.56 M	$3.16 M	$3.17 M
Interest Income	$15,000.00	$1.98 M	$0.00
Interest Expense	$211,000.00	$0.00	$0.00
Depreciation & Amortization	$0.00	$1.73 M	$484,000.00
EBITDA	-$5.56 M	-$1.43 M	-$2.69 M
EBITDA Ratio	0	0	0
Operating Income	-$5.56 M	-$3.16 M	-$3.17 M
Operating Income Ratio	0	0	0
Total Other Income/Expenses Net	$5.03 M	-$1.73 M	-$484,000.00
Income Before Tax	-$535,000.00	-$4.89 M	-$3.66 M
Income Before Tax Ratio	0	0	0
Income Tax Expense	$0.00	$374,862.00	$0.00
Net Income	-$535,000.00	-$4.89 M	-$3.66 M
Net Income Ratio	0	0	0
EPS	-0.008	-0.28	-0.21
EPS Diluted	-0.0079	-0.28	-0.21
Weighted Average Shares Out	$66.97 M	$17.29 M	$17.29 M
Weighted Average Shares Out Diluted	$67.89 M	$17.29 M	$17.29 M
Link

Conduit Pharmaceuticals Inc. (CDTTW) Financials